Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | PTGES | O14684 | 6/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.56 |
| ▸ | FNTA | P49354 | 4/20 | 0.52 |
| ▸ | FNTB | P49356 | 4/20 | 0.52 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3281840 | 0.90 | KMT2A (0.51) | MEN1KMT2APTGESALOX5FNTA | |
| SCHEMBL1723280 | 0.90 | KMT2A (0.49) | MEN1KMT2APTGESALOX5FNTA | |
| SCHEMBL2212915 | 0.88 | MEN1 (0.58) | MEN1KMT2APTGESALOX5FNTA | |
| SCHEMBL3279243 | 0.87 | FNTA (0.65) | MEN1KMT2APTGESALOX5FNTA | |
| SCHEMBL303692 | 0.86 | LMNA (0.66) | MEN1KMT2AFNTAFNTBPGGT1B | |
| SCHEMBL1722406 | 0.83 | LMNA (0.58) | MEN1KMT2AFNTAFNTBHPGD | |
| SCHEMBL1723248 | 0.83 | MEN1 (0.55) | MEN1KMT2AFNTAFNTBPGGT1B | |
| SCHEMBL3274787 | 0.83 | LMNA (0.52) | MEN1KMT2APTGESALOX5FNTA | |
| SCHEMBL1710991 | 0.82 | LMNA (0.47) | MEN1KMT2AFNTAFNTBALDH1A1 | |
| SCHEMBL1722971 | 0.80 | MEN1 (0.51) | MEN1KMT2APTGESALOX5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344456-B1 | NOVEL POTASSIUM CHANNEL BLOCKER | JAPAN TOBACCO INC (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-8258138-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2012-09-04 | — | — | US | disclosed |
| EP-2344456-A1 | NOVEL POTASSIUM CHANNEL BLOCKER | Xention Limited (GB) | 2011-07-20 | — | — | EP | disclosed |
| US-20100087437-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| WO-2010023445-A1 | NOVEL POTASSIUM CHANNEL BLOCKER | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087437-A1 | Novel Potassium Channel Blockers | KCNB1, KCNJ2, KCNJ11 | MEN1 824/4885KMT2A 777/4885PTGES 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.